References
- Hamilton B, Martin J, Ventura S. Births: preliminary data for 2010. National Center for Health Statistics National vital statistics reports web release [Internet]. 2011. Available from: http://www.cdc.gov/nchs/data/nvsr/nvsr60/nvsr60_02.pdf [last accessed 18 August 2012]
- Meis PJ, Klebanoff M, Thom E, et al. Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate. N Engl J Med 2003;348:2379–85
- Hendler I, Goldenberg RL, Mercer BM, et al. The preterm prediction study: association between maternal body mass index and spontaneous and indicated preterm birth. Am J Obstet Gynecol 2005;192:882–6
- Driul L, Cacciaguerra G, Citossi A, et al. Prepregnancy body mass index and adverse pregnancy outcomes. Arch Gynecol Obstet 2008;278:23–6
- Kumari AS. Pregnancy outcome in women with morbid obesity. Int J Gynaecol Obstet 2001;73:101–7
- Cnattingius S, Bergstrom R, Lipworth L, Kramer MS. Prepregnancy weight and the risk of adverse pregnancy outcomes. N Engl J Med 1998;338:147–52
- Caritis SN, Sharma S, Venkataramanan R, et al. Pharmacokinetics of 17-hydroxyprogesterone caproate in multifetal gestation. Am J Obstet Gynecol 2011;205:40. e1–8
- Sibai BM, Istwan NB, Palmer B, Stanziano GJ. Pregnancy outcomes of women receiving compounded 17 alpha-hydroxyprogesterone caproate for prophylactic prevention of preterm birth 2004 to 2011. Am J Perinatol 2012;29:635--42
- Society for Maternal Fetal Medicine Publications Committee. ACOG committee opinion number 419 October 2008 (replaces no. 291, November 2003). Use of progesterone to reduce preterm birth. Obstet Gynecol 2008;112:963–5
- Joy S, Istwan N, Rhea D, et al. The impact of maternal obesity on the incidence of adverse pregnancy outcomes in high-risk term pregnancies. Am J Perinatol 2009;26:345–9
- How HY, Barton JR, Istwan NB, et al. Prophylaxis with 17 alpha-hydroxyprogesterone caproate for prevention of recurrent preterm delivery: does gestational age at initiation of treatment matter? Am J Obstet Gynecol 2007;197:260. e1–4
- Gonzalez-Quintero VH, Istwan NB, Rhea DJ, et al. Gestational age at initiation of 17-hydroxyprogesterone caproate (17P) and recurrent preterm delivery. J Matern Fetal Neonatal Med 2007;20:249–52
- Ventolini G, Duke J, Po W, et al. The impact of maternal body mass on the effectiveness of 17 alpha-hydroxyprogesterone caproate. J Reprod Med 2008;53:667–71
- Ehrenberg HM, Iams JD, Goldenberg RL, et al. Maternal obesity, uterine activity, and the risk of spontaneous preterm birth. Obstet Gynecol 2009;113:48–52
- Caughey AB, Stotland NE, Washington AE, Escobar GJ. Who is at risk for prolonged and postterm pregnancy? Am J Obstet Gynecol 2009;200:683. e1–5
- Stotland NE, Washington AE, Caughey AB. Prepregnancy body mass index and the length of gestation at term. Am J Obstet Gynecol 2007;197:378. e1–5